Evidence map›Paper›PMID 41604064›Full record

ArticleInternational journal of hematology2026

Impact of diagnosis-to-treatment interval in relapsed or refractory diffuse large B-cell lymphoma.

Keita Ishii, Kazuhito Suzuki, Tadahiro Gunji, Ryoko Fukushima, Hiroto Ishii, Hideki Uryu, Hirofumi Yamauchi, Kurumi Tsukamoto, Kei Hirano, Riku Nagao and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keita IshiiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8567, Japan. h25ms-ishii@jikei.ac.jp.ORCID http://orcid.org/0000-0001-7872-4226
Kazuhito SuzukiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Japan.
Tadahiro GunjiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Japan.
Ryoko FukushimaDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Daisan Hospital, Komae, Japan.
Hiroto IshiiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Japan.
Hideki UryuDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Japan.
Hirofumi YamauchiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Daisan Hospital, Komae, Japan.
Kurumi TsukamotoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Daisan Hospital, Komae, Japan.
Kei HiranoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8567, Japan.
Riku NagaoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8567, Japan.
Takashi NakamuraDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8567, Japan.
Takeshi SaitoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Daisan Hospital, Komae, Japan.
Kaichi NishiwakiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8567, Japan.
Shingo YanoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The diagnosis-to-treatment interval (DTI) has been identified as a prognostic factor in newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, its significance in relapsed or refractory DLBCL (R/R DLBCL) remains unclear. This study aimed to investigate the impact of DTI on survival outcomes in patients with R/R DLBCL. We reviewed the medical records of patients with R/R DLBCL who received second-line therapy. DTI at relapse or refractory disease (r/r DTI) was defined as the time from radiological diagnosis-to-treatment initiation, with a cut-off of 28 days. The primary endpoint was overall survival (OS). A total of 184 patients with R/R DLBCL were included. Patients with short r/r DTI had significantly worse OS than those with long r/r DTI (1-year OS: 50.4% vs. 79.5%; P < 0.001). Short r/r DTI was associated with adverse clinical features, including poor performance status, elevated lactate dehydrogenase levels, and high International Prognostic Index at relapse. Multivariate analysis demonstrated that short r/r DTI was independently associated with significantly inferior OS (HR 1.77; P = 0.043). In conclusion, DTI is an independent prognostic factor in R/R DLBCL and can be considered in patient selection for clinical trials.

Indexed as

Lymphoma, Large B-Cell, DiffuseTime-to-TreatmentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedPrognosisRecurrenceRetrospective StudiesRituximabSurvival RateTreatment OutcomeRituximabClinical trialDiagnosis-to-treatment intervalRelapsed or refractory diffuse large B-cell lymphoma

Identifiers

PMID41604064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.